Towards a quality assurance for dosimetry in peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE

被引：0
|
作者：
Marin, G. [1 ]
Vanderlinden, B. [1 ]
Wimana, Z. [1 ]
Guiot, T. [1 ]
Karfis, I. [1 ]
Flamen, P. [1 ]
机构：
[1] Inst Jules Bordet, B-1000 Brussels, Belgium
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP386
引用
收藏
页码：S159 / S160
页数：2
相关论文
共 50 条
  • [41] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Mina M. Swiha
    Duncan E. K. Sutherland
    Golmehr Sistani
    Alireza Khatami
    Rami M. Abazid
    Amol Mujoomdar
    Daniele P. Wiseman
    Jonathan G. Romsa
    Robert H. Reid
    David T. Laidley
    [J]. Journal of Cancer Research and Clinical Oncology, 2022, 148 : 225 - 236
  • [42] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Jie Zhang
    Qi Song
    Liang Cai
    Ying Xie
    Yue Chen
    [J]. Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1533 - 1543
  • [43] Impaired Kidney Function Is Associated with Higher Absorbed Dose to Organs-at-Risk in 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT)
    Marin, G.
    Karfis, I
    Levillain, H.
    Reynaert, N.
    Vandenberghe, S.
    Vanderlinden, B.
    Flamen, P.
    [J]. NEUROENDOCRINOLOGY, 2019, 108 : 221 - 221
  • [44] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Zhang, Jie
    Song, Qi
    Cai, Liang
    Xie, Ying
    Chen, Yue
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (06) : 1533 - 1543
  • [45] Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
    Levart, D.
    Kalogianni, E.
    Corcoran, B.
    Mulholland, N.
    Vivian, G.
    [J]. EJNMMI PHYSICS, 2019, 6 (1)
  • [46] Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer
    Kasi, Pashtoon M.
    Sharma, Akash
    Jain, Manoj K.
    [J]. CASE REPORTS IN ONCOLOGY, 2019, 12 (01): : 98 - 103
  • [47] 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors
    Jahn, Ulrika
    Ilan, Ezgi
    Sandstrom, Mattias
    Garske-Roman, Ulrike
    Lubberink, Mark
    Sundin, Anders
    [J]. NEUROENDOCRINOLOGY, 2020, 110 (7-8) : 662 - 670
  • [48] Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the phase I-II Milan protocol
    Bodei, L.
    Cremonesi, M.
    Grana, C. M.
    Baio, S. M.
    Bartolomei, M.
    Ferrari, M.
    Iodice, S.
    Lombardo, D.
    Martano, L.
    Chinol, M.
    Paganelli, G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S266 - S267
  • [49] A Prospective study of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE and Concurrent Capecitabine in Metastatic Paragangliomas
    Ballal, S.
    Yadav, M. P.
    Yadav, D.
    Bal, C.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S184 - S184
  • [50] Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
    Lisa Bodei
    Marta Cremonesi
    Chiara M. Grana
    Nicola Fazio
    Simona Iodice
    Silvia M. Baio
    Mirco Bartolomei
    Dario Lombardo
    Mahila E. Ferrari
    Maddalena Sansovini
    Marco Chinol
    Giovanni Paganelli
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 : 2125 - 2135
12345